Immune-based therapies have shown limited efficacy in glioma thus far. This might be at
least in part due to insufficient numbers of neoantigens, thought to be targets of immune …

Background Gliomas are heterogeneous in the tumor immune microenvironment (TIM).
However, a classification of gliomas based on immunogenomic profiling remains lacking …

Simple Summary Tumor mutation burden (TMB) has shown promise as a biomarker for
immune checkpoint blockade therapy in some cancers, but not consistently in gliomas. The …

Glioblastoma (GBM) generates a varied immune response and understanding the immune
microenvironment may lead to novel immunotherapy treatments modalities. The goal of this …

Tumor mutation burden (TMB) is a useful biomarker to predict prognosis and the efficacy of
immune checkpoint inhibitors (ICIs). In this study, we aimed to explore the prognostic value …

The immunosuppressive microenvironment in glioblastoma (GBM) prevents an efficient
antitumoral immune response and enables tumor formation and growth. Although an …

Background Glioma is the most common type of primary brain tumor in adults. Patients with
the most malignant form have an overall survival time of< 16 months. Although considerable …

The tumor micro-environment (TME) plays an important role in various cancers, including
gliomas. We estimated immune cell type-specific gene expression profiles in 3 large …

High grade gliomas are malignant brain tumors that arise in the central nervous system, in
patients of all ages. Currently, the standard of care, entailing surgery and chemo radiation …

Glioblastoma (GBM) is resistant to multimodality therapeutic approaches. A high burden of
tumor-specific mutant peptides (neoantigens) correlates with better survival and response to …